Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21194508 | 0.92 | TGFBR1 (0.48) | TGFBR1KDM4EPKMGPR119MAPT | |
| SCHEMBL29160799 | 0.87 | TGFBR1 (0.54) | TGFBR1KDM4EPKMGPR119MAPT | |
| SCHEMBL20771440 | 0.87 | KDM4E (0.57) | TGFBR1KDM4EPKMGPR119MAPT | |
| SCHEMBL23003379 | 0.85 | NAMPT (0.51) | TGFBR1KDM4EPKMGPR119 | |
| SCHEMBL26665931 | 0.85 | TGFBR1 (0.53) | TGFBR1KDM4EPKMGPR119MAPT | |
| SCHEMBL6402117 | 0.85 | TGFBR1 (0.53) | TGFBR1KDM4EPKMGPR119MAPT | |
| SCHEMBL5573225 | 0.85 | KDM4E (0.63) | TGFBR1KDM4EPKMGPR119 | |
| SCHEMBL21664401 | 0.84 | SCN9A (0.52) | TGFBR1MAPT | |
| SCHEMBL372033 | 0.82 | NR1H2 (0.54) | KDM4EPKMGPR119 | |
| SCHEMBL627965 | 0.82 | KDM4E (0.60) | TGFBR1KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | TGFBR1 1225/4885KDM4E 2286/4885PKM 3252/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | TGFBR1 2309/4885KDM4E 2203/4885PKM 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.